Filing Flows › Arcus Biosciences (RCUS) › How it makes money
How Arcus Biosciences (RCUS) makes money
Arcus Biosciences (RCUS) made $9.0M of revenue in the third quarter 2026 (Q3 2026), -65% from a year earlier. License and development services brought in $8.0M (89%); Other collaboration brought in $1.0M (11%).
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| License and development services | $8.0M | 88.9% | -50% | -60% |
| Other collaboration | $1.0M | 11.1% | -96% | -83% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $9.0M | 100.0% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $9.0M | -65% |
| Q2 2026 | $41.0M | -74% |
| Q1 2026 | $17.0M | -39% |
| Q4 2025 | $33.0M | +27% |
| Q3 2025 | $26.0M | -46% |
| Q1 2025 | $28.0M | -81% |
From Arcus Biosciences' 10-Q filed Nov 4, 2026 (on EDGAR).
Questions
How does Arcus Biosciences make money?
Arcus Biosciences (RCUS) made $9.0M of revenue in the third quarter 2026 (Q3 2026), -65% from a year earlier. License and development services brought in $8.0M (89%); Other collaboration brought in $1.0M (11%).
What is Arcus Biosciences' biggest business?
License and development services: $8.0M in the third quarter 2026, 89% of revenue, -60% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.